| $385M | ||
| $350M | ||
| $215M | ||
| $82M | ||
| $76M | ||
| $62M |
Buys | $447,931 | 5 | 17 |
Sells | $486,269 | 25 | 83 |
| Ramachandra Sumant | director | 1 | $115,220 | 0 | $0 | $115,220 |
| Newton Charles W. | Chief Financial Officer | 1 | $111,620 | 3 | $18,105 | $93,515 |
| Seely Lynn | President and CEO | 1 | $106,190 | 6 | $275,967 | $-169,777 |
| Klausner Richard | director | 1 | $94,942 | 0 | $0 | $94,942 |
| BRAWLEY OTIS W | director | 1 | $19,958 | 0 | $0 | $19,958 |
| Hill Stephen J. | Chief Operating Officer | 0 | $0 | 6 | $45,477 | $-45,477 |
| Lee Gary K. | Chief Scientific Officer | 0 | $0 | 6 | $62,819 | $-62,819 |
| Bulis Veronica Sanchez | VP, Corporate Controller | 0 | $0 | 4 | $83,901 | $-83,901 |
Lyell Immunopharma, Inc., a T cell reprogramming company, engages in developing T cell therapies for patients with solid tumors. The company develops therapies using technology platforms, such as Gen-R, an ex vivo genetic reprogramming technology to overcome T cell exhaustion; and Epi-R, an ex vivo epigenetic reprogramming technology to generate population of T cells with durable stemness. Its pipeline includes LYL797, a T cell product candidate for the treatment of non-small cell lung cancer and triple negative breast cancers; LYL845, that targets multiple solid tumors; and NY-ESO-1 for synovial sarcoma and other solid tumor indications. The company entered into research and development collaboration and license agreement with GlaxoSmithKline for NY-ESO-1 program. Lyell Immunopharma, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.
Over the last 12 months, insiders at Lyell Immunopharma, Inc. have bought $447,931 and sold $486,269 worth of Lyell Immunopharma, Inc. stock.
On average, over the past 5 years, insiders at Lyell Immunopharma, Inc. have bought $373,973 and sold $309,278 worth of stock each year.
Highest buying activity among insiders over the last 12 months: Ramachandra Sumant (director) — $115,220. Newton Charles W. (Chief Financial Officer) — $111,620. Seely Lynn (President and CEO) — $106,190.
The last purchase of 35,640 shares for transaction amount of $19,958 was made by BRAWLEY OTIS W (director) on 2025‑03‑31.
| 2026-02-11 | Sale | Seely Lynn | President and CEO | 7,455 0.0337% | $23.39 | $174,372 | +3.48% | |
| 2026-02-11 | Sale | Hill Stephen J. | Chief Operating Officer | 1,236 0.0056% | $23.39 | $28,910 | +3.48% | |
| 2026-02-11 | Sale | Lee Gary K. | Chief Scientific Officer | 1,671 0.0076% | $23.39 | $39,085 | +3.48% | |
| 2026-02-10 | Sale | Seely Lynn | President and CEO | 438 0.002% | $23.12 | $10,127 | +2.99% | |
| 2026-02-10 | Sale | Hill Stephen J. | Chief Operating Officer | 109 0.0005% | $23.12 | $2,520 | +2.99% | |
| 2026-02-10 | Sale | Lee Gary K. | Chief Scientific Officer | 147 0.0007% | $23.12 | $3,399 | +2.99% | |
| 2026-02-10 | Sale | Bulis Veronica Sanchez | VP, Corporate Controller | 254 0.0012% | $23.12 | $5,872 | +2.99% | |
| 2025-12-30 | Sale | Bulis Veronica Sanchez | VP, Corporate Controller | 936 0.0045% | $32.32 | $30,252 | -24.08% | |
| 2025-12-24 | Sale | Bulis Veronica Sanchez | VP, Corporate Controller | 1,136 0.0054% | $38.67 | $43,929 | -37.78% | |
| 2025-11-10 | Sale | Seely Lynn | President and CEO | 412 0.002% | $16.11 | $6,637 | +35.92% | |
| 2025-11-10 | Sale | Hill Stephen J. | Chief Operating Officer | 95 0.0005% | $16.12 | $1,531 | +35.92% | |
| 2025-11-10 | Sale | Lee Gary K. | Chief Scientific Officer | 138 0.0007% | $16.16 | $2,230 | +35.92% | |
| 2025-11-10 | Sale | Bulis Veronica Sanchez | VP, Corporate Controller | 239 0.0011% | $16.10 | $3,848 | +35.92% | |
| 2025-08-21 | Sale | Seely Lynn | President and CEO | 7,257 0.0374% | $10.54 | $76,518 | +96.43% | |
| 2025-08-21 | Sale | Hill Stephen J. | Chief Operating Officer | 1,004 0.0052% | $10.54 | $10,586 | +96.43% | |
| 2025-08-21 | Sale | Lee Gary K. | Chief Scientific Officer | 1,453 0.0075% | $10.54 | $15,320 | +96.43% | |
| 2025-08-21 | Sale | Newton Charles W. | Chief Financial Officer | 1,453 0.0075% | $10.54 | $15,320 | +96.43% | |
| 2025-08-12 | Sale | Seely Lynn | President and CEO | 406 0.0026% | $10.34 | $4,197 | +79.75% | |
| 2025-08-12 | Sale | Lee Gary K. | Chief Scientific Officer | 136 0.0009% | $10.34 | $1,406 | +79.75% | |
| 2025-08-12 | Sale | Hill Stephen J. | Chief Operating Officer | 94 0.0006% | $10.34 | $972 | +79.75% |
| Klausner Richard | director | 843365 3.9699% | $18.94M | 1 | 1 | |
| Ramachandra Sumant | director | 200000 0.9414% | $4.49M | 1 | 0 | |
| Seely Lynn | President and CEO | 74266 0.3496% | $1.67M | 1 | 6 | |
| BRAWLEY OTIS W | director | 35640 0.1678% | $800,474.40 | 1 | 0 | |
| Hill Stephen J. | Chief Operating Officer | 17795 0.0838% | $399,675.70 | 0 | 6 | |
| Lee Gary K. | Chief Scientific Officer | 16938 0.0797% | $380,427.48 | 0 | 6 | |
| Bulis Veronica Sanchez | VP, Corporate Controller | 15637 0.0736% | $351,207.02 | 0 | 4 | |
| Newton Charles W. | Chief Financial Officer | 15306 0.072% | $343,772.76 | 1 | 3 | |
| FRIEDMAN CATHY | director | 17648 0.0831% | $396,374.08 | 1 | 0 | <0.0001% |
$3,611,891 | 113 | 13.40% | $508.98M | |
$1,323,997 | 34 | 0.21% | $491.95M | |
$63,049,419 | 31 | 2.87% | $504.61M | |
$74,231,875 | 30 | 40.62% | $481.62M | |
$79,019,806 | 27 | 7.24% | $446.78M | |
$22,017,898 | 24 | 39.19% | $447.15M | |
$4,306,464 | 21 | 37.34% | $450.53M | |
$112,238,340 | 19 | 39.16% | $516.26M | |
$104,137,421 | 15 | 21.28% | $478.79M | |
$8,069,667 | 13 | -13.57% | $444.37M | |
$15,149,818 | 12 | 2.98% | $466.36M | |
$19,167,169 | 10 | 28.48% | $442.09M | |
$4,745,999 | 5 | -4.91% | $453.2M | |
$144,224 | 4 | 21.31% | $505.55M | |
$10,104,842 | 3 | 5.45% | $499.96M | |
$184,294 | 3 | -10.64% | $460.17M | |
$2,857,000 | 2 | -5.23% | $509.13M | |
$3,850,000 | 1 | -51.32% | $437.89M | |
Lyell Immunopharma, Inc. (LYEL) | $300,016 | 1 | -50.33% | $477.14M |
| Increased Positions | 33 | +53.23% | 3M | +32.5% |
| Decreased Positions | 21 | -33.87% | 370,412 | -3.73% |
| New Positions | 15 | New | 3M | New |
| Sold Out Positions | 5 | Sold Out | 72,323 | Sold Out |
| Total Postitions | 74 | +19.35% | 13M | +28.77% |
| Arch Venture Management, Llc | $79,958.00 | 13.14% | 2.76M | +938,438 | +51.55% | 2025-09-30 |
| Mwg Management Ltd. | $29,215.00 | 4.8% | 1.01M | 0 | 0% | 2025-09-30 |
| Foresite Capital Management Iv, Llc | $23,196.00 | 3.81% | 800,399 | 0 | 0% | 2025-09-30 |
| Vanguard Group Inc | $22,576.00 | 3.71% | 779,004 | +336,378 | +76% | 2025-09-30 |
| Orland Properties Ltd | $21,871.00 | 3.59% | 754,698 | 0 | 0% | 2025-09-30 |
| Decheng Capital Llc | $17,257.00 | 2.84% | 595,466 | 0 | 0% | 2025-09-30 |
| Almitas Capital Llc | $16,745.00 | 2.75% | 577,807 | -2,190 | -0.38% | 2025-09-30 |
| Foresite Capital Management V, Llc | $13,826.00 | 2.27% | 477,078 | +70,426 | +17.32% | 2025-09-30 |
| Venbio Partners Llc | $13,721.00 | 2.26% | 473,479 | 0 | 0% | 2025-09-30 |
| Citadel Advisors Llc | $9,838.00 | 1.62% | 339,491 | +68,208 | +25.14% | 2025-09-30 |